Videos

Ruth O’Regan, MD, discusses the utility of CDK4/6 inhibitors in breast cancer.

Dr. O’Regan on the Utility of CDK4/6 Inhibitors in Breast Cancer 

Articles

CDK4/6 inhibitors alone and/or in combination with HER2-directed therapies have been shown to elicit encouraging response rates and inhibit the growth of the cancer cells in HER2-positive breast cancer.

CDK4/6 Inhibitors Make Headway in HER2+ and Triple-Negative Breast Cancers

Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.

O'Regan Shares Insight on Biosimilar Revolution in Oncology

Ruth O’Regan, MD, and Adam M. Brufsky, MD, PhD, FACP, both discuss the emergence of trastuzumab biosimilars in breast cancer.

Experts Highlight Benefits and Challenges With Biosimilars in Breast Cancer

Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.

Dr. O'Regan on Biosimilar Education in Breast Cancer

Podcasts

We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.

University of Wisconsin Carbone Cancer Center

Latest from University of Wisconsin Carbone Cancer Center

New content coming soon, please check back later.